Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2024

This “Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Understanding

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview

The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.

VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.

Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor R&D. The therapies under development are focused on novel approaches for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs Chapters

This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs

SOK583A1: Sandoz Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like n AMD, DME, and RVO. SOK583A1 is a biosimilar ofAflibercept(Eylea).

It is currently in the Phase III stage of development for the treatment of w AMD and is being developed by Sandoz, a division ofNovartis.

VK-2809: Viking Therapeutics VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

It is currently in Phase II stage of development and is being developed by Viking Therapeutics.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor

There are approx. 40+ key companies which are developing the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor. The companies which have their Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.

Phases

This report covers around 40+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights

• Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs?
• How many Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Qilu Pharmaceuticals
• AngioLab
• Sinocelltech
• Alteogen
• Adverum Biotechnologies
• Boehringer Ingelheim
• Eyevensys
• Oxford BioMedica

Key Products

• SOK583A1
• SCD411
• SB15
• LY09004
• HLX04-O
• GNR-067
• Faricimab
• FYB203
• CKD-701
• ONS-5010
• BCD 300
• ALS-L1023
• SCT510A
• ALT-L9
• ADVM-022
• BI 836880
• EYS609
• OXB-203

This product will be delivered within 2 business days.